Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant nivolumab with or without relatlimab in resectable non-small cell lung cancer
NL-OMON52539Phase 2Recruiting
- Sponsor
- Universitätsmedizin Essen
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab and relatlimab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Universitätsmedizin Essen. Primary endpoint: Feasibility of preoperative immunotherapy. Started Mar 2022; status: recruiting.
02
Drugs
nivolumabrelatlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON52539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52539.